Mersana Therapeutics Inc (MRSN)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Anna Protopapas |
| Employees: | 150 |
| Web site: | mersana.com |
|
840 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139
617-498-0020
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Mersana Therapeutics, Inc. develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for ovarian cancer and NSCLC adenocarcinoma.
Please log in first to see chart